A US study to evaluate transarterial radioembolization (TARE) in combination with durvalumab and bevacizumab therapy in people with unresectable hepatocellular carcinoma amenable to TARE

Trial Identifier: D933GC00002
Sponsor: AstraZeneca
Start Date: February 2024
Primary Completion Date: October 2026
Study Completion Date: October 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, CO Aurora, CO, US, 80045
US, FL Gainesville, FL, US, 32608
US, FL Orlando, FL, US, 32804
US, GA Atlanta, GA, US, 30322
US, GA Atlanta, GA, US, 30342
US, IL Chicago, IL, US, 60611
US, MA Boston, MA, US, 02118
US, MI Detroit, MI, US, 48201
US, MO Saint Louis, MO, US, 63110
US, NC Chapel Hill, NC, US, 27599
US, NJ Trenton, NJ, US, 08690
US, NY Buffalo, NY, US, 14263
US, NY New York, NY, US, 10029
US, OH Columbus, OH, US, 43210
US, OR Portland, OR, US, 97239
US, PA Philadelphia, PA, US, 19107
US, TX Houston, TX, US, 77030
US, VA Charlottesville, VA, US, 22908
US, WA Seattle, WA, US, 98195
US, WI Milwaukee, WI, US, 53215
US, WI Milwaukee, WI, US, 53226